The partners hope to bring a unique cancer treatment to the marketplace.
Moffitt Cancer Center and CvergenX Inc., two of Tampa Bay's health care technology development specialists, have entered into an agreement with global implications.
CvergenX is the exclusive holder of worldwide licensing rights for a radiation therapy technology called InterveneXRT, a platform developed by Moffitt. CvergenX will now attempt to commercialize the product, which personalizes patient treatment.
"The license agreement is one of the key milestones established for the company in 2010," said CvergenX CEO Mary Del Brady. “We are poised to proceed with the commercialization of InterveneXRT, including studies across multiple disease sites and, later, the opening of an independent advanced diagnostics laboratory.”
CvergenX will pay Moffitt as certain commercialization milestones are reached, although those milestones were not specified in the release. Moffitt is also entitled to collect royalties on future product sales.
Both the Moffitt Cancer Center and CvergenX Inc. are based in Tampa.